PRagmatic Trial Of Messaging to Providers About Treatment of Heart Failure (PROMPT-HF) at Inova
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Inova Health Care Services
- Enrollment
- 5,000
- Locations
- 1
- Primary Endpoint
- Increased use of GDMT in patients with Heart Failure with Reduced Ejection Fraction
Study Overview
Brief Summary
A randomized, single-blind intervention trial to test the comparative effectiveness of an electronic health record best practice advisory system that informs clinicians of guideline-indicated and FDA-approved heart failure medications currently not prescribed to their patients with heart failure versus usual care (no alert and how things are done currently). The purpose of the alert is to stimulate appropriate medication prescription for patients with heart failure and a reduced ejection fraction. This will be done across outpatient Inova clinics and at the five Inova hospitals.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Other
- Masking
- Single (Participant)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age>18 Years
- •Seen by a Cardiologist in an Inova clinic or Inova hospital setting
- •Left Ventricular Ejection Fraction ≤40%
Exclusion Criteria
- •Opted out of EHR-based research
- •Hospice care
- •Already receiving maximally titrated doses of each of the four classes of evidence- based HFrEF medical therapy
- •Prior heart transplant
Arms & Interventions
Alert when provider is entering orders
Intervention: Best Practice Advisory using Electronic Health Record (Other)
No alert, usual care
Outcomes
Primary Outcomes
Increased use of GDMT in patients with Heart Failure with Reduced Ejection Fraction
Time Frame: 30 days after randomization
The primary outcome for the trial will be the proportion of patients with HFrEF who have an increase in the number of prescribed evidence-based therapies for HFrEF (beta-blockers, ACE-I/ARB/ARNI, MRA, SGLT2i) 30 days after randomization.
Secondary Outcomes
- All-cause hospitalization and all-cause mortality at 1 year(1 year)
- All-cause hospitalization and all-cause mortality at 30 days(30 days)
- All-cause hospitalization and all-cause mortality at 90 days(90 days)
- All-cause hospitalization and all-cause mortality at 180 days(180 days)